Manova first three quarters net profit of 141 million

On October 22, Manova issued a report for the third quarter of 2020. The announcement showed that the revenue from January to September 2020 was 948,233,712.32 yuan, a year-on-year increase of 11.37%; the net profit attributable to shareholders of listed companies was 141,025,306.99 yuan, a year-on-year increase of 10.21%.

As of the end of the reporting period, Minova’s net assets attributable to shareholders of listed companies were RMB 1,521,450,797.63, an increase of 11.53% over the end of the previous year; the net cash flow from operating activities was RMB 224,146,747.56, a year-on-year increase of 102.73%.

The announcement showed that the operating income during the reporting period was 948,233,700 yuan, an increase of 96,830,400 yuan over the same period of the previous year, an increase of 11.37%, mainly because the company's specialty API business, preparation business and CDMO business have increased to a certain extent.

Sales expenses were RMB 15,354,300, an increase of RMB 1,109,900 from the same period of last year, mainly due to changes in expenses corresponding to the increase in sales revenue.

According to the data from digbei.com, Manova is mainly engaged in the research and development, production and sales of pharmaceutical intermediates, specialty APIs and preparations.